Aquestive therapeutics to present positive data from pharmacokinetic and pharmacodynamic studies of anaphylm™ (epinephrine) sublingual film at the cfaar food allergy summit

Warren, n.j., june 25, 2025 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (“aquestive” or the “company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of anaphylm™ (epinephrine) sublingual film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the center for food allergy and asthma research (cfaar) food allergy summit , which will be held june 27-29 in chicago, ill. the data from these posters was originally presented at the 2025 aaaai annual meeting. if approved by the u.s. food and drug administration (fda), anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the united states.
AQST Ratings Summary
AQST Quant Ranking